0001193125-22-292016.txt : 20221123 0001193125-22-292016.hdr.sgml : 20221123 20221123160637 ACCESSION NUMBER: 0001193125-22-292016 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221118 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20221123 DATE AS OF CHANGE: 20221123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Comera Life Sciences Holdings, Inc. CENTRAL INDEX KEY: 0001907685 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41403 FILM NUMBER: 221416391 BUSINESS ADDRESS: STREET 1: 12 GILL STREET STREET 2: SUITE 4650 CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 617.871.2101 EXT 313 MAIL ADDRESS: STREET 1: 12 GILL STREET STREET 2: SUITE 4650 CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 d410213d8k.htm 8-K 8-K
false 0001907685 0001907685 2022-11-18 2022-11-18 0001907685 us-gaap:CommonStockMember 2022-11-18 2022-11-18 0001907685 us-gaap:WarrantMember 2022-11-18 2022-11-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2022

 

 

Comera Life Sciences Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   1-41403   87-4706968

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

12 Gill Street

Suite 4650

Woburn, Massachusetts

  01801
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 871-2101

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock   CMRA   The Nasdaq Stock Market LLC
Warrants   CMRAW   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


Item 3.01.

Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing.

On November 18, 2022, Comera Life Sciences Holdings, Inc. (the “Company”) received a letter from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq listing rule 5550(b)(2).

The notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Capital Market under the symbol “CMRA.”

In accordance with Nasdaq listing rule 5810(c)(3)(C), the Company has 180 calendar days, or until May 17, 2023, to regain compliance. The notice states that to regain compliance, the Company’s MVLS must close at $35 million or more for a minimum of ten consecutive business days (or such longer period of time as the Nasdaq staff may require in some circumstances, but generally not more than 20 consecutive business days) during the compliance period ending May 17, 2023. The Company may also regain compliance by meeting the continued listing standard of a minimum stockholders’ equity of at least $2.5 million.

If the Company does not regain compliance by May 17, 2023, Nasdaq staff will provide written notice to the Company that its securities are subject to delisting. At that time, the Company may appeal any such delisting determination to a Nasdaq hearings panel.

The Company intends to actively monitor the Company’s MVLS between now and May 17, 2023, and may, if appropriate, evaluate available options to resolve the deficiency and regain compliance with the MVLS rule. While the Company is exercising diligent efforts to maintain the listing of its common stock on Nasdaq, there can be no assurance that the Company will be able to regain or maintain compliance with Nasdaq listing standards.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 23, 2022   COMERA LIFE SCIENCES HOLDINGS, INC.
  By:  

/s/ Jeffrey S. Hackman

  Name:   Jeffrey S. Hackman
  Title:   Chairman, President and Chief Executive Officer
EX-101.SCH 2 cmra-20221118.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 3 cmra-20221118_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 cmra-20221118_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Warrant [Member] Warrant [Member] EX-101.PRE 5 cmra-20221118_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 18, 2022
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001907685
Document Type 8-K
Document Period End Date Nov. 18, 2022
Entity Registrant Name Comera Life Sciences Holdings, Inc.
Entity Incorporation State Country Code DE
Entity File Number 1-41403
Entity Tax Identification Number 87-4706968
Entity Address, Address Line One 12 Gill
Entity Address, Address Line Two Street
Entity Address, Address Line Three Suite 4650
Entity Address, City or Town Woburn
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01801
City Area Code (617)
Local Phone Number 871-2101
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock
Trading Symbol CMRA
Security Exchange Name NASDAQ
Warrant [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Warrants
Trading Symbol CMRAW
Security Exchange Name NASDAQ
XML 7 d410213d8k_htm.xml IDEA: XBRL DOCUMENT 0001907685 2022-11-18 2022-11-18 0001907685 us-gaap:CommonStockMember 2022-11-18 2022-11-18 0001907685 us-gaap:WarrantMember 2022-11-18 2022-11-18 false 0001907685 8-K 2022-11-18 Comera Life Sciences Holdings, Inc. DE 1-41403 87-4706968 12 Gill Street Suite 4650 Woburn MA 01801 (617) 871-2101 false false false false Common Stock CMRA NASDAQ Warrants CMRAW NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 3 25 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d410213d8k.htm cmra-20221118.xsd cmra-20221118_def.xml cmra-20221118_lab.xml cmra-20221118_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d410213d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "cmra-20221118_def.xml" ] }, "inline": { "local": [ "d410213d8k.htm" ] }, "labelLink": { "local": [ "cmra-20221118_lab.xml" ] }, "presentationLink": { "local": [ "cmra-20221118_pre.xml" ] }, "schema": { "local": [ "cmra-20221118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 32, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 2, "nsprefix": "cmra", "nsuri": "http://comeralifesciences.com/20221118", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d410213d8k.htm", "contextRef": "duration_2022-11-18_to_2022-11-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d410213d8k.htm", "contextRef": "duration_2022-11-18_to_2022-11-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "cmra_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://comeralifesciences.com/20221118", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "cmra_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://comeralifesciences.com/20221118", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://comeralifesciences.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001193125-22-292016-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-292016-xbrl.zip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